Abstract:Krabbe disease (KD) is an autosomal recessive lysosomal storage disorder caused by loss–of–function mutations in the GALC gene, which encodes for the enzyme galactosylceramidase (GALC). GALC is crucial for myelin metabolism. Functional deficiency of GALC leads to toxic accumulation of psychosine, dysfunction and death of oligodendrocytes, and eventual brain demyelination. To date, 46 clinically–relevant, pathogenic GALC missense mutations (MMs) have been identified in KD patients. These MMs are present in ~70% of KD cases reported over 8 published studies between 1996 – 2019. However, the mechanisms by which these MMs lead to GALC functional deficiency and their correlations with clinical phenotype remain poorly understood. To address this, we generated a GALC–knockout human oligodendrocytic cell line (MO3.13/ GALC–KO) using CRISPR–Cas9 method to assess GALC function and GALC secretion. We evaluated 5 polymorphic and 31 clinically–relevant MM variants (MMVs) using transient expression assays. Our results showed that 26 MMVs, including 10 co–variants with p.I562T, reduced GALC activity by 92% – 100% compared to wildtype GALC (WT–GALC). MMVs from infantile-onset KD patients produced < 2% of WT activity, whereas those associated with juvenile– and adult–onset cases retained up to 7% of WT activity. Residual GALC activity was correlated with mature, lysosomal GALC protein levels (Pearson r = 0.93, P<0.0001). Many low–activity MMVs did not correspondingly impair GALC secretion. Twenty–one of the 26 low–activity MMVs showed a 21% – 100% reduction in sec–GALC levels, indicating varying degrees of GALC mis–trafficking among these variants. Importantly, GALC activity among MMVs strongly correlates with clinical disease severity, based on the age of symptom onset in patients with either homozygous MM (Pearson r = 0.98, P<0.0001, n = 7) or compound heterozygous (Pearson r = 0.94, P<0.0001, n = 12) MM–null mutation genotypes. Thus, our data suggests that GALC activity could serve as a prognostic disease indicator under specific experimental conditions. We further investigated the impact of pathogenic MMVs on psychosine accumulation, a key biomarker for KD. Psychosine levels were 21–fold higher in mock control cells compared to WT–GALC transfected cells (mock = 0.349 pmol/mg, WT–GALC = 0.016 pmol/mg), but negatively correlated with GALC activity among pathogenic MMVs (Pearson r = –0.63, P < 0.01, n = 15). Although psychosine levels were higher in most MMVs associated with infantile–onset KD, no significant correlations with clinical onset were detected. Overall, our study provides a comprehensive quantitative analysis of the functional deficits and mis–trafficking associated with clinically–relevant GALC MMVs, enhancing our understanding of the molecular genetics and genotype–phenotype correlations of the GALC gene in Krabbe disease.

A novel brain-penetrant oral UGT8 inhibitor decreases in vivo galactosphingolipid biosynthesis in murine Krabbe disease

Substrate reduction therapy for Krabbe disease and metachromatic leukodystrophy using a novel ceramide galactosyltransferase inhibitor

Genetic ablation of acid ceramidase in Krabbe disease confirms the psychosine hypothesis and identifies a new therapeutic target

Efficacy and Safety of a Krabbe Disease Gene Therapy

CRISPR-Cas9 Knock-In of T513M and G41S Mutations in the Murine β–Galactosyl-Ceramidase Gene Re-capitulates Early-Onset and Adult-Onset Forms of Krabbe Disease

Brain Targeted AAV1-GALC Gene Therapy Reduces Psychosine and Extends Lifespan in a Mouse Model of Krabbe Disease

Chronic Rapamycin administration via drinking water mitigates the pathological phenotype in a Krabbe disease mouse model through autophagy activation

Decreasing ganglioside synthesis delays motor and cognitive symptom onset in knockout mice

Krabbe disease: New hope for an old disease

A Novel Cereblon Modulator Recruits GSPT1 to the CRL4 CRBN Ubiquitin Ligase

Abstract SY37-02: Ligand-directed Degradation of GSPT1 by a Novel Cereblon Modulator Drives Potent Antitumor Effects

Substrate Reduction Therapy Reverses Mitochondrial, mTOR, and Autophagy Alterations in a Cell Model of Gaucher Disease

Galactosylceramidase deficiency and pathological abnormalities in cerebral white matter of Krabbe disease

Infantile Krabbe disease (0–12 months), progression, and recommended endpoints for clinical trials

The Effect of Donepezil Hydrochloride in the Twitcher Mouse Model of Krabbe Disease

P‐glycoprotein (MDR1/ABCB1) controls brain accumulation and intestinal disposition of the novel TGF‐β signaling pathway inhibitor galunisertib

Development and Validation of Leukocyte Enzyme Activity Assay by LC-MS/MS for Diagnosis of Krabbe Disease and Other Lysosomal Storage Diseases

RP-CARS reveals molecular spatial order anomalies in myelin of an animal model of Krabbe disease

P3‐299: Chronic Administration of a Novel BACE Inhibitor Reduced Brain Aβ Levels and Mature Plaques and Modestly Improved Cognition in Transgenic CRND8‐APPswe/ind Mice

Expression study of Krabbe Disease GALC missense variants — Insights from quantification profiles of residual enzyme activity, secretion and psychosine levels

The selective GSK3 inhibitor, SAR502250, displays neuroprotective activity and attenuates behavioral impairments in models of neuropsychiatric symptoms of Alzheimer’s disease in rodents